Patent · US Active

Treatment of cerebral palsy impaired speech in children

US9155502B2 · kind B2 · utility

0Cited by

4References

20Claims

0Family size

Assignee

GILROSE PHARMACEUTICALS, LLC · US

Inventors

Bruce Roseman · White Plains, US
Gilla Kaplan · New York, US

Key dates

Filing date	Aug 6, 2014
Grant date	Oct 13, 2015
Priority date	—
Expiry date	Aug 6, 2034

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61B5/4064
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Cerebral palsy impaired speech in children and adolescents are effectively treated by administration of a psychostimulant. Low doses of the psychostimulant significantly increases the percentage of correctly pronounced intelligible syllables or words and the ability to more intelligibly communicate. The improvement in speech persists after cessation of or prior to continued psychostimulant treatment.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.